Business Description
Plus Therapeutics Inc
NAICS : 339112
SIC : 3841
ISIN : US23283K4022
Total Employee Number:
28Description
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 20.85 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.09 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 72.1 | |||||
3-Year EPS without NRI Growth Rate | 71.9 | |||||
3-Year FCF Growth Rate | 67.6 | |||||
3-Year Book Growth Rate | -78.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 63.75 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 113.17 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 22.14 | |||||
9-Day RSI | 20.78 | |||||
14-Day RSI | 18.79 | |||||
3-1 Month Momentum % | -79.25 | |||||
6-1 Month Momentum % | -79.25 | |||||
12-1 Month Momentum % | -79.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.27 | |||||
Quick Ratio | 2.27 | |||||
Cash Ratio | 1.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -295 | |||||
Shareholder Yield % | -134.43 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -14766.09 | |||||
ROA % | -77.16 | |||||
ROIC % | -487.86 | |||||
3-Year ROIIC % | 113.85 | |||||
ROC (Joel Greenblatt) % | -1867.72 | |||||
ROCE % | -173.2 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.27 | |||||
Price-to-Tangible-Book | 2.4 | |||||
EV-to-EBIT | -1.45 | |||||
EV-to-EBITDA | -1.52 | |||||
EV-to-Forward-EBITDA | -0.56 | |||||
EV-to-Forward-Revenue | 2.78 | |||||
EV-to-FCF | -0.59 | |||||
| Price-to-Net-Current-Asset-Value | 2.68 | |||||
| Price-to-Net-Cash | 3.79 | |||||
Earnings Yield (Greenblatt) % | -68.97 | |||||
FCF Yield % | -79.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Plus Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.857 | ||
| Beta | 1.4985 | ||
| 3-Year Sharpe Ratio | -0.5 | ||
| 3-Year Sortino Ratio | -0.6 | ||
| Volatility % | 86.06 | ||
| 14-Day RSI | 18.79 | ||
| 14-Day ATR (€) | 0.225187 | ||
| 20-Day SMA (€) | 4.38975 | ||
| 12-1 Month Momentum % | -79.25 | ||
| 52-Week Range (€) | 3.36 - 28.15 | ||
| Shares Outstanding (Mil) | 6.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Plus Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Plus Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-30 | In 127 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 50 days | ||
| Plus Therapeutics to Provide Business Update Call | 2026-06-30 08:30 | In 6 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 4.77 (+0.00%) | ||
| General meeting for 2026 | 2026-05-14 09:00 | 4.89 (+0.00%) | ||
| 0.04:1 Stock Split | 2026-04-02 | 28.15 (+0.00%) | ||
| Annual report for 2025 | 2026-03-12 | 28.15 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 28.15 (+0.00%) | ||
| Plus Therapeutics Business Update Conference Call | 2026-01-22 09:00 | 28.15 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-10-30 | 28.15 (+0.00%) |
Show
Entries
Plus Therapeutics Inc Frequently Asked Questions
What is Plus Therapeutics Inc(FRA:XMP1)'s stock price today?
The current price of FRA:XMP1 is €3.49. The 52 week high of FRA:XMP1 is €28.15 and 52 week low is €3.36.
When is next earnings date of Plus Therapeutics Inc(FRA:XMP1)?
The next earnings date of Plus Therapeutics Inc(FRA:XMP1) is 2026-08-14 Est..
Does Plus Therapeutics Inc(FRA:XMP1) pay dividends? If so, how much?
Plus Therapeutics Inc(FRA:XMP1) does not pay dividend.
Press Release
Articles on Plus Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers